CN109069504B - 氨基噻唑化合物及其用途 - Google Patents
氨基噻唑化合物及其用途 Download PDFInfo
- Publication number
- CN109069504B CN109069504B CN201780010118.4A CN201780010118A CN109069504B CN 109069504 B CN109069504 B CN 109069504B CN 201780010118 A CN201780010118 A CN 201780010118A CN 109069504 B CN109069504 B CN 109069504B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- compounds
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291667P | 2016-02-05 | 2016-02-05 | |
| US62/291,667 | 2016-02-05 | ||
| PCT/US2017/015765 WO2017136315A1 (en) | 2016-02-05 | 2017-01-31 | Aminothiazole compounds and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109069504A CN109069504A (zh) | 2018-12-21 |
| CN109069504B true CN109069504B (zh) | 2022-06-28 |
Family
ID=59496120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780010118.4A Active CN109069504B (zh) | 2016-02-05 | 2017-01-31 | 氨基噻唑化合物及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10047078B2 (enExample) |
| EP (1) | EP3411035B1 (enExample) |
| JP (1) | JP6883049B2 (enExample) |
| KR (1) | KR102449712B1 (enExample) |
| CN (1) | CN109069504B (enExample) |
| ES (1) | ES2909612T3 (enExample) |
| TW (1) | TWI620748B (enExample) |
| WO (1) | WO2017136315A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| DK3322706T3 (da) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| JP7301958B2 (ja) | 2018-05-25 | 2023-07-03 | オンコキューブ セラピューティクス エルエルシー | 新規な抗がん薬候補としての非常に強力なｔａｃｃ３阻害剤 |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| CN117460724A (zh) * | 2021-04-12 | 2024-01-26 | A2A制药有限公司 | 用于治疗癌症的组合物和方法 |
| KR20250005157A (ko) | 2022-03-24 | 2025-01-09 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225880A1 (en) * | 2011-03-04 | 2012-09-06 | National Health Research Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| US20130150364A1 (en) * | 2010-08-10 | 2013-06-13 | Astellas Pharma Inc. | Heterocyclic compound |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2308833A3 (en) * | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| HUP0303538A2 (hu) * | 2000-12-21 | 2005-02-28 | Bristol-Myers Squibb Co. | Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények |
| EP1558609A4 (en) * | 2002-10-30 | 2008-05-28 | Merck & Co Inc | KINASE INHIBITORS |
| CA2593803A1 (en) * | 2005-01-26 | 2006-08-03 | Irm Llc | Thiazole-amide compounds and compsitions as protein kinase inhibitors |
| PL2268635T3 (pl) | 2008-04-21 | 2015-11-30 | Taigen Biotechnology Co Ltd | Związki heterocykliczne |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| CN104024246B (zh) * | 2012-03-27 | 2016-03-02 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
-
2017
- 2017-01-26 TW TW106103165A patent/TWI620748B/zh active
- 2017-01-30 US US15/419,183 patent/US10047078B2/en active Active
- 2017-01-31 KR KR1020187024997A patent/KR102449712B1/ko active Active
- 2017-01-31 JP JP2018560435A patent/JP6883049B2/ja active Active
- 2017-01-31 EP EP17747997.9A patent/EP3411035B1/en active Active
- 2017-01-31 ES ES17747997T patent/ES2909612T3/es active Active
- 2017-01-31 WO PCT/US2017/015765 patent/WO2017136315A1/en not_active Ceased
- 2017-01-31 CN CN201780010118.4A patent/CN109069504B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130150364A1 (en) * | 2010-08-10 | 2013-06-13 | Astellas Pharma Inc. | Heterocyclic compound |
| US20120225880A1 (en) * | 2011-03-04 | 2012-09-06 | National Health Research Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180132618A (ko) | 2018-12-12 |
| ES2909612T3 (es) | 2022-05-09 |
| JP2019511564A (ja) | 2019-04-25 |
| US10047078B2 (en) | 2018-08-14 |
| EP3411035B1 (en) | 2022-03-02 |
| WO2017136315A1 (en) | 2017-08-10 |
| HK1258689A1 (zh) | 2019-11-15 |
| US20170226100A1 (en) | 2017-08-10 |
| TWI620748B (zh) | 2018-04-11 |
| EP3411035A4 (en) | 2019-08-14 |
| CN109069504A (zh) | 2018-12-21 |
| EP3411035A1 (en) | 2018-12-12 |
| TW201728583A (zh) | 2017-08-16 |
| KR102449712B1 (ko) | 2022-09-30 |
| JP6883049B2 (ja) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109069504B (zh) | 氨基噻唑化合物及其用途 | |
| KR102618773B1 (ko) | 디아릴 거대환형 화합물을 수반하는 병용 요법 | |
| JP7058345B2 (ja) | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 | |
| JP6637884B2 (ja) | ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法 | |
| TW202007396A (zh) | Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途 | |
| TWI726362B (zh) | Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用 | |
| KR20100135754A (ko) | 병용 요법 238 | |
| CN114867622A (zh) | 涉及二芳基巨环化合物的组合疗法 | |
| AU2022201717B2 (en) | Treatment of cancer | |
| CN114901286B (zh) | 涉及二芳基巨环化合物的组合疗法 | |
| JP2020523348A (ja) | プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 | |
| PT2182948E (pt) | Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr | |
| KR20240004548A (ko) | 암 치료를 위한 pcna 억제제 및 egfr 억제제 | |
| WO2015112705A2 (en) | Therapeutic combinations for treating cancer | |
| CN112237579B (zh) | 药物组合及其用途 | |
| HK1258689B (en) | Aminothiazole compounds and use thereof | |
| JP7200453B2 (ja) | Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体 | |
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ | |
| RU2784853C2 (ru) | Комбинационная терапия с применением диарильных макроциклических соединений | |
| HK40035225A (en) | Pharmaceutical combination and use thereof | |
| EP4441052A1 (en) | Compounds | |
| HK40017909A (en) | Aminothiazole compounds as protein kinase inhibitors | |
| ZA200306404B (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190325 Address after: Miaoli County, Taiwan, China Applicant after: National Health Research Institutes Address before: Miaoli County, Taiwan, China Applicant before: National Health Research Institutes Applicant before: Shi Quan |
|
| TA01 | Transfer of patent application right | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1258689 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Address after: Miaoli County, Taiwan, China Applicant after: Taiwan Institute of health Address before: Miaoli County, Taiwan, China Applicant before: NATIONAL HEALTH RESEARCH INSTITUTES |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jiang Weitang Inventor after: Xu Shi Inventor before: Jiang Weitang Inventor before: Xu Chu |
|
| CB03 | Change of inventor or designer information |